个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Genomic characteristics and prognosis of lung cancer patients with MSI-H: A cohort study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Tian Jie[1] * ; Wang Hongdan[1] * ; Lu Conghua[1] * ; Liu Lan[1] * ; Zhang Xianquan[2] ; Xie Yunbo[3] ; Li Rutian[4] ; Lv Xin[4] ; Fu Dan[5] ; Zhang Ling[6] ; Fang Xisheng[7] ; Wang Xuming[8] ; Hu Jing[9] ; Liu Xinyi[5] ; Huang Xiaochun[5] ; Zhao Qian[1] ; Luo Nuo[1] ; Tang Huan[1] ; Zhong Zhaoyang[10] ; He Yong[1] ; Li Li[1,11] ;
机构： [1]Department of Respiratory Medicine, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, China. [2]The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. [3]The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. [4]Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. [5]3D Medicines Inc., Shanghai, China. [6]The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China. [7]Department of Medical Oncology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China. [8]The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China. [9]Chongqing General Hospital, University of Chinese Academy of Sciences, Chongqing, China. [10]Department of Cancer Center, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, China. [11]Department of Respiratory Medicine, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing 400042, China
出处：
DOI： 10.1016/j.lungcan.2023.107255
ISSN：

关键词： Microsatellite Instability-High (MSI-H) Microsatellite Stability (MSS) Lung cancer Genetic characteristics EGFR

摘要：
Microsatellite instability (MSI) is the first pan-cancer biomarker approved to guide immune checkpoint inhibitor therapy for MSI-high (MSI-H) solid tumors. In lung cancer, the MSI-H frequency is very low, and the genetic characteristics and prognosis of lung cancer with MSI-H were rarely reported.Next-generation sequencing and immunohistochemistry were used detect MSI status, tumor mutation burden (TMB) and PD-L1 expression.Among 12,484 lung cancer patients screened, 66 were found with MSI-H, the proportion was as low as 0.5%. Compared with Microsatellite stability (MSS), TMB was higher in MSI-H lung cancer patients, while PD-L1 expression showed no considerable difference between MSI-H and MSS. After propensity score matching, compared with MSS, the most common companion mutations in MSI-H were TP53, BRCA2, TGFBR2, PTEN and KMT2C. In MSI-H lung adenocarcinoma with EGFR mutation, TGFBR2 and ERBB2 had higher mutation frequency than in MSS.The current study reveals the genetic characteristics of MSI-H lung cancer, which advanced our understanding of MSI-H lung cancer.Copyright © 2023. Published by Elsevier B.V.

基金：
National Natural Science Foundation of China (82272908), Natural Science Foundation of Chongqing (2022NSCQ-MSX3880), The Science Foundation for Outstanding Young People of the Army Medical University (40137-2780), The Science Foundation of Daping Hospital, Army Medical University (2019CXLCB011).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学 3 区 呼吸系统
最新[2023]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学 3 区 呼吸系统
JCR分区：
出版当年[2022]版：
Q2 ONCOLOGY Q2 RESPIRATORY SYSTEM
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [1]Department of Respiratory Medicine, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
共同第一作者：
通讯作者：
通讯机构： [1]Department of Respiratory Medicine, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, China. [11]Department of Respiratory Medicine, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing 400042, China
推荐引用方式(GB/T 7714)：
Tian Jie,Wang Hongdan,Lu Conghua,et al.Genomic characteristics and prognosis of lung cancer patients with MSI-H: A cohort study[J].LUNG CANCER.2023,181:doi:10.1016/j.lungcan.2023.107255.
APA：
Tian Jie,Wang Hongdan,Lu Conghua,Liu Lan,Zhang Xianquan...&Li Li.(2023).Genomic characteristics and prognosis of lung cancer patients with MSI-H: A cohort study.LUNG CANCER,181,
MLA：
Tian Jie,et al."Genomic characteristics and prognosis of lung cancer patients with MSI-H: A cohort study".LUNG CANCER 181.(2023)

相关文献

[1]Mutational Profile of Multiple Lung Cancers in Xuanwei by Next-Generation Sequencing [2]Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition) [3]Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study [4]Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant A Randomized Clinical Trial [5]Small cell lung cancer transformation after EGFR-TKIs treatment in lung adenocarcinoma: A case report and literatures review [6]TMB is associated with the prognosis of egfr-mutated non-small cell lung cancer in Xuanwei, China [7]Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) [8]Next-Generation Sequencing Reveals High Uncommon EGFR Mutations and Tumour Mutation Burden in a Subgroup of Lung Cancer Patients [9]Mining whole-lung information by artificial intelligence for predicting EGFR genotype and targeted therapy response in lung cancer: a multicohort study. [10]Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M mutated non-small cell lung cancer that had progressed after prior EGFR TKI therapy: A phase 2, multicenter, single-arm, open-label study.

资源点击量：86881 今日访问量：0 总访问量：706 更新日期：2025-03-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持：重庆聚合科技有限公司 地址：云南省昆明市西山区金碧路157号